Executive Summary
In cardiac care, the choice between surgery and stenting is rarely trivial — and when two respected specialists in two different countries reach opposite conclusions, the member is left caught in the middle. For an internationally insured member moving between health systems, the resolution of that disagreement depends on something most patients never see: an assistance partner with the clinical governance to reconcile conflicting expert recommendations before a single approval is issued.
In mid-2026, Prospera Medical Assistance managed exactly such a case. A 56-year-old Indian expatriate working in the UAE suffered an acute anterior-wall ST-elevation myocardial infarction (STEMI) in Dubai. Coronary angiography revealed complex multivessel coronary artery disease, and the treating team in Dubai recommended Coronary Artery Bypass Grafting (CABG) — open-heart surgery. The member elected to pursue treatment in his home country, India, where an interventional cardiologist reviewed the same findings and advised a less invasive alternative: Percutaneous Coronary Intervention (PCI / angioplasty).
This left a clinically significant discrepancy — surgery advised in one country, stenting in another — for a member who was expected to return to Dubai after treatment. Proceeding without resolving that discrepancy risked the worst of both worlds: an angioplasty in India that might later be judged inadequate back in the UAE, potentially forcing a repeat or alternative revascularization, with all the added clinical risk and cost that would entail.
Rather than simply approving the cheaper option or defaulting to the more invasive one, Prospera Medical Assistance did what expert case governance demands. We flagged the discrepancy and referred the case to Prospera Medical Assistance’s Second Medical Opinion (SMO) advisory panel — our standing team of independent specialists — for a definitive surgical review by a consultant cardiothoracic (cardiac) surgeon, the very specialty that performs CABG. Prospera’s advisory panel concurred that the member was a suitable candidate for PCI and did not require bypass surgery at that stage.
With both the treating interventional cardiologist and Prospera Medical Assistance’s SMO advisory panel aligned on the same strategy, Prospera Medical Assistance assembled a defensible clinical justification, secured the insurer’s approval, and coordinated fully cashless treatment. The member underwent successful PCI to the LAD with a drug-eluting stent in India, was discharged in stable condition, and returned home with a revascularization strategy endorsed by two independent specialties — delivered at a fraction of the cost of surgical bypass.
Patient Overview
| Parameter |
Details |
| Patient |
Mr. (identity withheld for confidentiality) |
| Nationality |
Indian national (expatriate employed in the UAE) |
| Age / Gender |
56 Years / Male |
| Diagnosis |
Ischaemic Heart Disease; Acute Anterior Wall STEMI; Multivessel Coronary Artery Disease (LVEF 35–40%) |
| Relevant History |
Known IHD; prior PCI (stent) to the right coronary artery (2020) |
| Insurance Provider |
Salama Insurance (UAE) |
| Index Event Managed At |
Treating hospital, Dubai, UAE |
| Revascularization Performed At |
ACE Heart Hospital, Mumbai, India |
| Treatment Type |
Percutaneous Coronary Intervention (PCI / PTCA) to the LAD with drug-eluting stent |
| Case Period |
June 2026 – July 2026 |
The Challenge
This case did not turn on a hard-to-reach hospital or an exotic diagnosis. It turned on judgement — reconciling two legitimate but opposing expert recommendations across two health systems, without exposing the member to under-treatment, over-treatment, or a duplicated procedure. The challenges Prospera Medical Assistance had to navigate were:
-
Conflicting cross-border recommendations — CABG (open-heart surgery) was advised in Dubai, while PCI (angioplasty) was advised in India for the same coronary anatomy. Approving either option blindly carried real clinical and financial risk.
-
A member returning to the country of the opposing opinion — the member was expected to return to Dubai after treatment. If an Indian angioplasty were later deemed insufficient in the UAE, a second revascularization could follow — compounding risk, recovery time, and cost.
-
Complex, high-stakes coronary anatomy — a post-infarct patient with multivessel disease, a critical proximal LAD lesion, reduced left-ventricular function (LVEF 35–40%) and a prior coronary stent — precisely the profile where the surgery-versus-stent decision must be made carefully.
-
The need for defensible medical governance — the insurer could not reasonably approve a departure from the original surgical recommendation on the strength of a single dissenting opinion. Robust, multidisciplinary clinical justification was required before any approval could be issued.
-
Cross-border coordination — the member, the insurer, and the treating providers spanned two countries, two regulatory environments, and two sets of clinical documentation standards, all of which had to be reconciled into a single coherent case file.
-
Balancing clinical appropriateness with cost-effectiveness — the objective was never simply the cheapest pathway; it was the clinically correct pathway, which in this case also happened to be markedly more cost-effective. Getting there required evidence, not assumption.
What Prospera Medical Assistance Did Differently
1
Identified and Flagged the Treatment Discrepancy
Where a routine claims process might have simply actioned whichever recommendation arrived last, Prospera Medical Assistance recognized that a member had received two opposing revascularization recommendations across two countries — CABG in Dubai, PCI in India — and that the member intended to return to the UAE. We treated this not as a paperwork mismatch but as a clinical-governance question that had to be resolved before approval.
2
Engaged Prospera’s SMO Advisory Panel for a Surgical Second Opinion
Critically, Prospera Medical Assistance referred the case to its own Second Medical Opinion (SMO) advisory panel — a standing team of independent specialists Prospera convenes precisely for decisions of this kind — and specifically to a consultant cardiothoracic surgeon on the panel, the specialty that actually performs CABG. This was deliberate: rather than relying on a further interventional-cardiology view (which might be predisposed toward stenting), Prospera’s advisory panel brought a surgeon’s independent judgement to bear on whether the member genuinely required bypass surgery, or whether PCI was appropriate and sufficient for his coronary anatomy and clinical condition.
3
Achieved a Multidisciplinary Consensus
Prospera’s SMO advisory panel reviewed the available angiographic and clinical findings and concluded that the member was a suitable candidate for PCI / angioplasty and did not require CABG at that stage — that he could undergo and tolerate percutaneous intervention appropriately, with no immediate indication for surgical bypass. The PCI strategy was now supported by two independent specialties: interventional cardiology and cardiothoracic surgery.
4
Built a Defensible Clinical Justification for the Payer
Prospera Medical Assistance consolidated the angiographic findings, the echocardiographic assessment, the treating interventional cardiologist’s recommendation, and the concurring surgical opinion from Prospera’s SMO advisory panel into a single, coherent clinical justification — giving the insurer the evidence base needed to confidently approve a departure from the original surgical recommendation, rather than defaulting to the more invasive and costly option out of caution.
5
Secured Approval and Coordinated Cashless Treatment
With the multidisciplinary consensus documented, the insurer approved the proposed treatment plan. Prospera Medical Assistance placed the Guarantee of Payment and coordinated the member’s admission and PCI at ACE Heart Hospital, Mumbai on a fully cashless basis, with no upfront financial burden to the member, and managed the case end-to-end through to discharge.
6
Delivered the Clinically Correct — and More Cost-Effective — Pathway
The pathway Prospera Medical Assistance validated was not only clinically appropriate but substantially more cost-effective. PCI in India was delivered at an approved value of roughly AED 14,290 (approximately INR 375,700) — a fraction of the cost of surgical bypass, before even accounting for the risk and expense of a potential repeat procedure back in the UAE that the multidisciplinary review helped to pre-empt.
Clinical Journey Overview
Acute Presentation in Dubai
The member — a 56-year-old man with known ischaemic heart disease and a prior coronary stent (PCI to the right coronary artery in 2020) — presented with acute left-sided chest pain and was admitted under cardiology at the treating hospital in Dubai. Assessment confirmed an acute anterior-wall ST-elevation myocardial infarction (STEMI), with the ECG showing ST elevations across the anterior leads, and he was taken up for urgent evaluation.
Angiographic Findings and Initial Surgical Recommendation
Coronary angiography at the treating hospital in Dubai revealed complex multivessel coronary artery disease, including a critical, heavily calcified proximal LAD lesion and severe disease in the left circumflex territory. On the basis of these findings, the recommended strategy in Dubai was Coronary Artery Bypass Grafting (CABG). Definitive revascularization was not performed at that stage, and the member elected to pursue treatment in his home country, India.
Home-Country Evaluation in India
In India, the member was assessed by an interventional cardiologist. Echocardiography confirmed ischaemic heart disease with regional wall-motion abnormality — severe hypokinesia of the mid and apical anterior wall — and moderately depressed left-ventricular systolic function (LVEF approximately 40%), with only trivial valvular regurgitation and no pulmonary hypertension. Having reviewed the angiographic and clinical picture, the interventional cardiologist advised Percutaneous Coronary Intervention (PCI / PTCA) to the LAD as the preferred revascularization strategy, with medical management of the remaining disease.
The Discrepancy — and Why It Mattered
The two recommendations now stood in direct opposition: surgery (CABG) in Dubai versus stenting (PCI) in India. Because the member was expected to return to the UAE following treatment, Prospera Medical Assistance recognized that proceeding without reconciliation risked an angioplasty being later judged inadequate abroad — potentially triggering a repeat or alternative revascularization. Ensuring the intervention was genuinely appropriate for the member’s anatomy, before it was performed, became the priority.
Second Medical Opinion — Prospera’s SMO Advisory Panel
Prospera Medical Assistance referred the case to its Second Medical Opinion (SMO) advisory panel for an additional, independent specialist review, delivered by a consultant cardiothoracic (cardiac) surgeon on the panel. Reviewing the available angiographic and clinical information — including the multivessel disease, the reduced ejection fraction, and the wall-motion findings — the panel evaluated the feasibility of PCI versus surgical revascularization and concluded that the member was a suitable candidate for PCI / angioplasty and did not require CABG at that stage.
Multidisciplinary Consensus and Approval
With both the treating interventional cardiologist and Prospera’s SMO advisory panel aligned that PCI was appropriate and sufficient — and that surgical bypass was not required at that point — Prospera Medical Assistance presented the consolidated clinical justification to the insurer. Satisfied with the multidisciplinary basis for the plan, the insurer issued approval for coronary angioplasty (PCI) with drug-eluting stent, and Prospera Medical Assistance placed the Guarantee of Payment to enable cashless treatment.
Treatment and Outcome
At ACE Heart Hospital, Mumbai, the member underwent successful PCI to the LAD with one drug-eluting stent, performed via right radial access under local infiltration. The lesions were treated successfully with angioplasty and stent placement; the procedure was uneventful and well tolerated, with satisfactory post-procedure flow in the treated artery. He was monitored overnight, remained haemodynamically and clinically stable, and was discharged on optimized medical therapy with structured cardiology follow-up — carrying a revascularization strategy endorsed by both his treating cardiologist and Prospera’s SMO advisory panel.
Value Delivered
Across the full course of this case, Prospera Medical Assistance’s involvement delivered:
- A reconciled, multidisciplinary treatment decision — surgery-versus-stenting resolved through the consensus of the treating interventional cardiologist and Prospera’s SMO advisory panel, rather than by default.
- Protection against a duplicated procedure — proactive clinical review that helped pre-empt the risk of a repeat or alternative revascularization after the member’s return to the UAE.
- A defensible clinical justification for the payer — anchored by Prospera’s SMO advisory panel and a consolidated evidence base that allowed the insurer to approve the appropriate, less invasive pathway with confidence.
- Rapid GOP placement and fully cashless access — no upfront financial burden to the member, coordinated end-to-end.
- A clinically correct and markedly more cost-effective outcome — PCI delivered at roughly AED 14,290, a fraction of the cost of surgical bypass and any potential repeat intervention.
- Seamless cross-border coordination — member, insurer, and providers across two countries kept aligned through a single, coherent case file.
- A successful clinical result — an uneventful, well-tolerated procedure and a stable discharge, with the member reassured that the chosen strategy carried dual-specialty endorsement.
Cost Containment & Savings
Because the clinically correct pathway was also the more cost-effective one, the case delivered substantial, quantifiable savings. The table below sets the actual approved cost of the treatment Prospera Medical Assistance coordinated against the pathways that were avoided — the open-heart surgery originally recommended in Dubai, and the same angioplasty had it been performed in the UAE.
| Pathway |
Procedure & Location |
Indicative Cost (USD) |
Cost Contained vs Delivered |
| Originally recommended in Dubai |
CABG (open-heart bypass) — UAE |
≈ 12,250–24,230
AED 45,000–89,000 |
≈ 8,360–20,340
(68–84%) |
| Like-for-like alternative |
PCI with 1 drug-eluting stent — UAE |
≈ 9,530–14,980
AED 35,000–55,000 |
≈ 5,640–11,080
(59–74%) |
| Delivered by Prospera (home country) |
PCI with 1 drug-eluting stent — India |
≈ 3,890
AED 14,291 |
Baseline |
Delivered cost is the actual approved case value of AED 14,290.80 (≈ USD 3,890, converted at the pegged rate USD 1 = AED 3.6725).
UAE figures are indicative ranges for a comparable insured admission, spanning basic to median-level costs per DRG reference data (not retail self-pay package prices): CABG ≈ AED 45,000–89,000 (≈ USD 12,250–24,230); angioplasty (single-stent PCI) ≈ AED 35,000–55,000 (≈ USD 9,530–14,980). Savings are shown across the full range.
Figures exclude the additional cost and clinical risk avoided by pre-empting a potential repeat or alternative revascularization after the member’s return to the UAE.
Bottom line: against the open-heart surgery originally recommended in Dubai, Prospera Medical Assistance’s coordinated home-country PCI contained an estimated USD 8,400–20,300 (AED 30,700–74,700) — a reduction of roughly 68–84% — while delivering the treatment endorsed by both the treating cardiologist and Prospera’s SMO advisory panel.
Outcome
What began as a genuine clinical impasse — open-heart surgery advised in one country, angioplasty in another, for a member about to cross back between the two — was resolved into a single, defensible, dual-specialty consensus, and delivered as safe, cashless, cost-effective care. Managed end-to-end by Prospera Medical Assistance, the case produced the following outcomes:
- Discrepancy reconciled — CABG-versus-PCI resolved through a Second Medical Opinion from Prospera’s SMO advisory panel confirming PCI as appropriate.
- Dual-specialty endorsement — the final strategy supported by both the treating interventional cardiologist and Prospera’s SMO advisory panel (cardiothoracic surgery).
- Duplicate-procedure risk mitigated — proactive review reduced the likelihood of a repeat revascularization after the member’s return to the UAE.
- Fully cashless treatment — approval and Guarantee of Payment placed, with no upfront cost to the member.
- Successful revascularization — PCI to the LAD with a drug-eluting stent completed uneventfully, with a stable discharge.
- Cost-effective governance — the clinically correct pathway delivered at approximately AED 14,290, well below the cost of surgical bypass.
This case demonstrates what Prospera Medical Assistance delivers when the challenge is not access but judgement — reconciling conflicting expert opinions across borders, protecting the member from over-treatment and duplicated procedures, and giving the payer the clinical confidence to approve the right care. The disagreement was resolved. The member received appropriate, evidence-backed treatment. And the outcome was both clinically sound and cost-effective.